Ascentage Pharma FY26 H1 loss widens to US$120.4 million; revenue rises 29% to US$44.5 million
AAPG•First-half results
Ascentage Pharma revenue rose 29% year over year to US$44.5 million for the six months ended June 30, 2026.
Net loss widened to US$120.4 million; loss per share attributable to ordinary equity holders was US$0.32.
Costs and cash balance
Selling and distribution expenses climbed 64.3% to US$33.4 million, due to higher marketing and promotion investment for Lisaftoclax.
R&D expenses increased 32% to US$102.8 million; cash and bank balances fell 23.3% to US$279.4 million.
Corporate and clinical updates
The company added Dr. Faiçal Miyara as chief business officer and Jim Ziegler as chief commercial officer; nine registrational Phase III trials are ongoing globally.
